113 related articles for article (PubMed ID: 15340733)
1. [Postprandial hyperglycemia as a risk factor for cardiovascular disease. Therapy improves prognosis].
Hanefeld M; Schaper F
Herz; 2004 Aug; 29(5):480-7. PubMed ID: 15340733
[TBL] [Abstract][Full Text] [Related]
2. Postprandial hyperglycaemia and cardiovascular complications of diabetes: an update.
Ceriello A; Davidson J; Hanefeld M; Leiter L; Monnier L; Owens D; Tajima N; Tuomilehto J;
Nutr Metab Cardiovasc Dis; 2006 Oct; 16(7):453-6. PubMed ID: 16934443
[TBL] [Abstract][Full Text] [Related]
3. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia.
Milicevic Z; Raz I; Beattie SD; Campaigne BN; Sarwat S; Gromniak E; Kowalska I; Galic E; Tan M; Hanefeld M
Diabetes Care; 2008 Feb; 31 Suppl 2():S155-60. PubMed ID: 18227478
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
[TBL] [Abstract][Full Text] [Related]
5. Role of postprandial hyperglycemia in cardiovascular disease.
Fava S
Expert Rev Cardiovasc Ther; 2008 Jul; 6(6):859-72. PubMed ID: 18570623
[TBL] [Abstract][Full Text] [Related]
6. [Postprandial hyperglycemia and diabetic complications].
Da Ros R; Assaloni R; Ceriello A
Recenti Prog Med; 2005 Sep; 96(9):436-44. PubMed ID: 16229326
[TBL] [Abstract][Full Text] [Related]
7. Clinical decision making: managing postprandial hyperglycemia.
Hurel SJ; Mohan V
J Assoc Physicians India; 2006 Nov; 54():871-6. PubMed ID: 17249256
[TBL] [Abstract][Full Text] [Related]
8. Postprandial glucose regulation and diabetic complications.
Ceriello A; Hanefeld M; Leiter L; Monnier L; Moses A; Owens D; Tajima N; Tuomilehto J
Arch Intern Med; 2004 Oct; 164(19):2090-5. PubMed ID: 15505121
[TBL] [Abstract][Full Text] [Related]
9. Acute glucose fluctuations and chronic sustained hyperglycemia as risk factors for cardiovascular diseases in patients with type 2 diabetes.
Colette C; Monnier L
Horm Metab Res; 2007 Sep; 39(9):683-6. PubMed ID: 17846977
[TBL] [Abstract][Full Text] [Related]
10. Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus.
Delorme S; Chiasson JL
Curr Opin Pharmacol; 2005 Apr; 5(2):184-9. PubMed ID: 15780829
[TBL] [Abstract][Full Text] [Related]
11. Hyperglycaemic spikes as a risk factor of diabetic complications.
Szybiñski Z
Przegl Lek; 2006; 63 Suppl 4():1-2. PubMed ID: 16969903
[No Abstract] [Full Text] [Related]
12. [Hyperglycemia and cardiovascular events].
Schneider CA; Gallwitz B; Hanefeld M; Leschke M; Müller-Wieland D; Zeymer U; Erdmann E
Dtsch Med Wochenschr; 2004 Nov; 129(47):2553-7. PubMed ID: 15543474
[TBL] [Abstract][Full Text] [Related]
13. Glycaemic control is essential for effective cardiovascular risk reduction across the type 2 diabetes continuum.
Karasik A
Ann Med; 2005; 37(4):250-8. PubMed ID: 16019723
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
Zeymer U
Int J Cardiol; 2006 Feb; 107(1):11-20. PubMed ID: 16337493
[TBL] [Abstract][Full Text] [Related]
15. Fasting and postchallenge hyperglycemia and risk of cardiovascular disease in Chinese: the Chin-Shan Community Cardiovascular Cohort study.
Chien KL; Hsu HC; Su TC; Chen MF; Lee YT; Hu FB
Am Heart J; 2008 Nov; 156(5):996-1002. PubMed ID: 19061718
[TBL] [Abstract][Full Text] [Related]
16. [The best of epidemiology and cardiovascular prevention in 2006].
Thomas D; Collet JP; Cottin Y; Cournot M; Ducimetière P; Ferrières J; Paillard F; Valensi P; Zeller M; Cambou JP
Arch Mal Coeur Vaiss; 2007 Jan; 100 Spec No 1():57-64. PubMed ID: 17405566
[TBL] [Abstract][Full Text] [Related]
17. Primary prevention of cardiovascular disease in people with dysglycemia.
Bianchi C; Miccoli R; Penno G; Del Prato S
Diabetes Care; 2008 Feb; 31 Suppl 2():S208-14. PubMed ID: 18227487
[TBL] [Abstract][Full Text] [Related]
18. Defining the role of incretin mimetic therapy in the management of type 2 diabetes.
Unger J; Nadeau DA
J Fam Pract; 2007 Dec; 56(12 Suppl New):S4-S10. PubMed ID: 18664341
[TBL] [Abstract][Full Text] [Related]
19. Postprandial hyperglycaemia in type 2 diabetes: pathophysiological aspects, teleological notions and flags for clinical practice.
Boutati EI; Raptis SA
Diabetes Metab Res Rev; 2004; 20 Suppl 2():S13-23. PubMed ID: 15551342
[TBL] [Abstract][Full Text] [Related]
20. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor.
O'Keefe JH; Bell DS
Am J Cardiol; 2007 Sep; 100(5):899-904. PubMed ID: 17719342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
